Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valaciclovir to improve influenza vaccine immunity in CMV-positive older adults
ISRCTN24967173Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Nov 2011
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of valaciclovir in cytomegalovirus disease (CMV), immunosenescence and influenza (7 arms), sponsored by University of Birmingham. Primary endpoint: Magnitude of the CMV-specific CD8+ T-cell immune response at month 12. Started Nov 2011; status: completed.
02
Drugs
valaciclovir
03
Conditions
cytomegalovirus disease (CMV)immunosenescenceinfluenza
Beyond the preview
Go deeper on ISRCTN24967173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN24967173.